Author
B. Bui-Nguyen
Bio: B. Bui-Nguyen is an academic researcher. The author has contributed to research in topics: Imatinib mesylate & GiST. The author has an hindex of 11, co-authored 12 publications receiving 1962 citations.
Topics: Imatinib mesylate, GiST, Ifosfamide, Chemotherapy regimen, Sunitinib
Papers
More filters
Radboud University Nijmegen1, Seoul National University Hospital2, Katholieke Universiteit Leuven3, University of Turin4, University of Pennsylvania5, Institut Gustave Roussy6, Leiden University Medical Center7, The Royal Marsden NHS Foundation Trust8, European Organisation for Research and Treatment of Cancer9, GlaxoSmithKline10, Harvard University11, Brigham and Women's Hospital12
TL;DR: This phase 3 study investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.
1,671 citations
TL;DR: Ridaforolimus delayed tumor progression to a small statistically significant degree in patients with metastatic sarcoma who experienced benefit with prior chemotherapy and provided a foundation on which to further improve control of sarcomas.
Abstract: Purpose Aberrant mammalian target of rapamycin (mTOR) signaling is common in sarcomas and other malignancies. Drug resistance and toxicities often limit benefits of systemic chemotherapy used to treat metastatic sarcomas. This large randomized placebo-controlled phase III trial evaluated the mTOR inhibitor ridaforolimus to assess maintenance of disease control in advanced sarcomas. Patients and Methods Patients with metastatic soft tissue or bone sarcomas who achieved objective response or stable disease with prior chemotherapy were randomly assigned to receive ridaforolimus 40 mg or placebo once per day for 5 days every week. Primary end point was progression-free survival (PFS); secondary end points included overall survival (OS), best target lesion response, safety, and tolerability. Results A total of 711 patients were enrolled, and 702 received blinded study drug. Ridaforolimus treatment led to a modest, although significant, improvement in PFS per independent review compared with placebo (hazard rat...
199 citations
TL;DR: Nilotinib was well tolerated and provided significantly longer median OS in patients with advanced gastrointestinal stromal tumors following prior imatinib and sunitinib failure.
120 citations
TL;DR: In GIST patients, presence of a KIT exon 11 mutation is an independent prognostic factor for PFS and OS, along with gender, PS, tumour size, lymphocyte and neutrophil counts.
61 citations
TL;DR: Data show that adding masitinib to the armaterium of drugs used to treat GIST generates a clinically relevant survival benefit.
60 citations
Cited by
More filters
University of Milan1, Instituto Português de Oncologia Francisco Gentil2, Curie Institute3, Leiden University Medical Center4, Vienna General Hospital5, University College London6, Leiden University7, Institut Jules Bordet8, Netherlands Cancer Institute9, Turku University Hospital10, University of Oxford11, University of Mannheim12, Ludwig Maximilian University of Munich13, Helsinki University Central Hospital14, The Royal Marsden NHS Foundation Trust15, Institute of Cancer Research16, University Medical Center Groningen17, Radboud University Nijmegen18, Institut Gustave Roussy19, Tel Aviv Sourasky Medical Center20, University Hospital of Lausanne21, University of Bologna22, University of Turin23, Weston Park Hospital24, Aarhus University Hospital25, Katholieke Universiteit Leuven26, Erasmus University Rotterdam27, Oslo University Hospital28, University College Hospital29, Claude Bernard University Lyon 130
1,150 citations
TL;DR: In this paper, the authors summarize lessons learned from preclinical and clinical studies over the past decade and propose strategies for improving antiangiogenic therapy outcomes for malignant and nonmalignant diseases.
1,093 citations
Harvard University1, University of Ulsan2, Claude Bernard University Lyon 13, Leiden University Medical Center4, University of Mannheim5, Fox Chase Cancer Center6, Helsinki University Central Hospital7, University of Palermo8, Mount Sinai Hospital, Toronto9, Institut Gustave Roussy10, Katholieke Universiteit Leuven11, Icahn School of Medicine at Mount Sinai12, University of Duisburg-Essen13, Academy of Military Medical Sciences14, Bayer HealthCare Pharmaceuticals15
TL;DR: The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on standard treatments.
1,079 citations
TL;DR: The present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench are addressed.
Abstract: The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.
1,075 citations
TL;DR: The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.
Abstract: For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.
838 citations